Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8028855 | 0.80 | LMNA (0.37) | ALDH1A1LMNAALOX15BLMPMP22 | |
| SCHEMBL1515458 | 0.76 | — | — | |
| SCHEMBL1515257 | 0.75 | — | — | |
| SCHEMBL1515477 | 0.74 | CA2 (0.35) | TSHRLMNABLMPMP22 | |
| SCHEMBL4295108 | 0.74 | — | — | |
| SCHEMBL4954270 | 0.74 | — | — | |
| SCHEMBL5010520 | 0.73 | — | — | |
| SCHEMBL1370896 | 0.73 | — | — | |
| SCHEMBL10002465 | 0.72 | — | — | |
| SCHEMBL11972356 | 0.72 | EGFR (0.36) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908911-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-06-21 | — | — | US | claimed |
| EP-1210330-B1 | ANTIBACTERIAL AGENTS | VERNALIS OXFORD LTD (GB) | 2005-04-20 | — | — | EP | claimed |
| EP-1210330-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-06-05 | — | — | EP | claimed |
| WO-2001010835-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | claimed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| CN-110709085-A | Compounds and methods for treating visceral pain | 艾尼纳制药公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-8778950-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | disclosed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-6908911-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-06-21 | — | — | US | disclosed |
| EP-1210330-B1 | ANTIBACTERIAL AGENTS | VERNALIS OXFORD LTD (GB) | 2005-04-20 | — | — | EP | disclosed |
| EP-1210330-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001010835-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885TSHR 1295/4885FGFR4 2698/4885 |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | ALDH1A1 603/4885TSHR 4484/4885FGFR4 3821/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885TSHR 1295/4885FGFR4 2698/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885TSHR 1295/4885FGFR4 2698/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885TSHR 1295/4885FGFR4 2698/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | ALDH1A1 603/4885TSHR 4484/4885FGFR4 3821/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885TSHR 1295/4885FGFR4 2698/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885TSHR 1295/4885FGFR4 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.